advertisement
Abstract #11342 Published in IGR 6-3
Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma
Christiansen GA; Nau CB; McLaren JW; Johnson DHOphthalmology 2004; 111: 1658-1662
PURPOSE: To determine the mechanism of ocular hypotensive action of bimatoprost in patients with ocular hypertension or glaucoma. DESIGN: Double-masked, placebo-controlled, randomized, paired comparison crossover study of the effect of bimatoprost on aqueous humor dynamics. PARTICIPANTS AND CONTROLS: Twenty-nine patients with ocular hypertension or glaucoma. METHODS: Bimatoprost and a placebo were administered once a day, in the evening, for 7 days before assessment of aqueous dynamics using tonometry, Schiotz tonography, and fluorophotometry. Intraocular pressure (IOP) response to water drinking was measured. MAIN OUTCOME MEASURES: Aqueous humor flow rate, outflow facility, and IOP. RESULTS: Intraocular pressure was lowered 29% in the morning and 33% at noon by bimatoprost. Aqueous humor flow was unchanged. Tonographic facility of outflow was increased 47% by bimatoprost relative to the placebo. Assuming an extraocular pressure of 8 mmHg and that extraocular pressure is not altered by bimatoprost, the calculated rate of pressure-insensitive outflow was increased 95% by bimatoprost. During the first hour after water drinking, bimatoprost dampened the IOP rise. CONCLUSION: As was seen in healthy normal eyes, bimatoprost increased both the pressure-sensitive and the pressure-insensitive outflows of aqueous humor in patients with ocular hypertension or glaucoma. Bimatoprost had no significant effect on aqueous humor formation.
Dr. G.A. Christiansen, Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
